Popular weight loss drugs linked to higher risk of stomach paralysis

Popular weight loss drugs linked to higher risk of stomach paralysis
Popular weight loss drugs linked to higher risk of stomach paralysis

Thank you for reading the news about Popular weight loss drugs linked to higher risk of stomach paralysis and now with the details

Jeddah - Yasmine El Tohamy - WASHINGTON: Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday.
The paper, published in the Journal of the American Medical Association (JAMA), looked at a class of drugs called GLP-1 agonists that includes the brands Wegovy, Ozempic, Rybelsus and Saxenda.
It then compared the rate of serious side effects to another class of weight loss drug, bupropion-naltrexone.
The GLP-1 agonists were associated with an almost four times increased risk of stomach paralysis, a nine times higher risk of pancreatitis and four times greater risk of bowel obstruction.
These conditions can cause hospitalization and require surgery, depending on their severity.
“Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss,” said lead author Mohit Sodhi, a medical student at the University of British Columbia in Canada, in a statement.
“The risk calculus will differ depending on whether a patient is using these drugs for diabetes, obesity or just general weight loss,” he added. “People who are otherwise healthy may be less willing to accept these potentially serious adverse events.”
Originally developed for managing Type 2 diabetes, GLP-1 agonists have soared in popularity in recent years as a means to lose weight, mainly through “off-label” use.
Saxenda and Wegovy were approved for weight loss in 2020 and 2021, but the clinical trials used to greenlight them involved too few people with too short a follow-up time to detect very rare events, the researchers said.
Epidemiologist and co-author Mahyar Etminan said that while there had been anecdotal reports of some patients using these drugs for weight loss and then having repeated episodes of nausea and vomiting as a result of stomach paralysis, the current study was the first to examine the question at a larger scale.
The authors trawled through US patient records searching for people prescribed liraglutide or semaglutide — the two main GLP-1 agonists — or bupropion/naltrexone, a non GLP-1 weight loss medication, to see how many went on to develop certain gastrointestinal conditions.
Their analysis included patients with a recent history of obesity, but excluded those with diabetes or who had been prescribed another antidiabetic drug. Just over 5,400 records were included in the final analysis.
“The results from this study highlight how important it is that patients access these drugs only through trusted medical professionals, and only with ongoing support and monitoring,” said Simon Cork, a senior lecturer at Anglia Ruskin University, who was not involved in the research.
“It is vital that regulation is tightened to ensure that these drugs are only prescribed under the right circumstances.”

These were the details of the news Popular weight loss drugs linked to higher risk of stomach paralysis for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Arab News and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Russian bombing raids kill three in eastern Ukraine
NEXT FBI director warns that Chinese hackers are preparing to ‘wreak havoc’ on US critical infrastructure

Author Information

I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community. Address: 2077 Sharon Lane Mishawaka, IN 46544, USA Phone: (+1) 574-255-1083 Email: [email protected]